Non-operative management of mismatch repair-deficient (dMMR) / micro satellite instability-high (MSI-H) colorectal cancer treated with immunotherapy: systematic review and meta-analysis - Takeaways - MDSpire

Non-operative management of mismatch repair-deficient (dMMR) / micro satellite instability-high (MSI-H) colorectal cancer treated with immunotherapy: systematic review and meta-analysis

  • By

  • Jih Huei Tan

  • Ian Wee Jun Yan

  • Jasmine Hui Er Chang

  • Michelle Shi Qing Khoo

  • Thomas Jun Yao Tan

  • Emile John Kwong Wei Tan

  • February 17, 2026

  • 0 min

Share

  • 1

    Immune checkpoint inhibitors have established immunotherapy as the first-line treatment for dMMR/MSI-H colorectal cancer.

  • 2

    Neoadjuvant immunotherapy shows high efficacy in locally advanced colorectal cancer, potentially allowing omission of surgery.

  • 3

    The meta-analysis found a local relapse rate of 0% and two-year recurrence-free survival rates approaching 100% in non-operative management.

  • 4

    Organ preservation was achieved in over 90% of patients, with low-grade immune-related adverse events reported.

  • 5

    Future trials are needed to standardize treatment protocols and assess long-term outcomes in non-operative management of colorectal cancer.

Original Source(s)

Related Content